Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Becocalcidiol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VDR known ✓ | P11473 | 11/20 | 0.76 |
| ▸ | CYP24A1 | Q07973 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Becocalcidiol SCHEMBL14489149 | 1.00 | VDR (0.76) | VDRCYP24A1 | |
| Becocalcidiol SCHEMBL9010345 | 1.00 | VDR (0.76) | VDRCYP24A1 | |
| Becocalcidiol SCHEMBL9009884 | 1.00 | VDR (0.76) | VDRCYP24A1 | |
| Becocalcidiol SCHEMBL23752369 | 1.00 | VDR (0.76) | VDRCYP24A1 | |
| Becocalcidiol SCHEMBL859793 | 1.00 | VDR (0.76) | VDRCYP24A1 | |
| Becocalcidiol SCHEMBL23752370 | 1.00 | VDR (0.76) | VDRCYP24A1 | |
| Becocalcidiol SCHEMBL9009928 | 1.00 | VDR (0.76) | VDRCYP24A1 | |
| Becocalcidiol SCHEMBL10820222 | 1.00 | VDR (0.76) | VDRCYP24A1 | |
| Becocalcidiol SCHEMBL13666147 | 1.00 | VDR (0.76) | VDRCYP24A1 | |
| Becocalcidiol SCHEMBL798548 | 1.00 | VDR (0.76) | VDRCYP24A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080096851-A1 | (20S)-1Alpha-Hydroxy-2-Methylene-19-Nor-Bishomopregnacalciferol and Its Uses | WISCONSIN ALUMNI RESEARCH FOUNDATION, A NON-STOCK, NON-PROFIT WISCONSIN CORPORATION (US) | 2008-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096851-A1 | (20S)-1Alpha-Hydroxy-2-Methylene-19-Nor-Bishomopregnacalciferol and Its Uses | CYP24A1, CYP27B1, CYP2R1 | VDR 4/4885CYP24A1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.